Elanco Animal Health Incorporated (NYSE:ELAN) Stake Lowered by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund cut its position in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 42.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 167,841 shares of the company's stock after selling 124,674 shares during the period. Illinois Municipal Retirement Fund's holdings in Elanco Animal Health were worth $2,501,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in the company. Treasurer of the State of North Carolina lifted its position in Elanco Animal Health by 0.5% during the third quarter. Treasurer of the State of North Carolina now owns 221,460 shares of the company's stock worth $2,489,000 after buying an additional 1,107 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its position in Elanco Animal Health by 10.2% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 12,123 shares of the company's stock worth $181,000 after buying an additional 1,127 shares in the last quarter. Ieq Capital LLC raised its position in Elanco Animal Health by 10.8% in the third quarter. Ieq Capital LLC now owns 13,464 shares of the company's stock valued at $151,000 after purchasing an additional 1,311 shares during the period. AMG National Trust Bank raised its position in Elanco Animal Health by 1.1% in the third quarter. AMG National Trust Bank now owns 122,526 shares of the company's stock valued at $1,377,000 after purchasing an additional 1,332 shares during the period. Finally, Vanguard Personalized Indexing Management LLC raised its position in Elanco Animal Health by 2.6% in the third quarter. Vanguard Personalized Indexing Management LLC now owns 61,540 shares of the company's stock valued at $692,000 after purchasing an additional 1,546 shares during the period. 97.48% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

ELAN has been the topic of a number of research analyst reports. Barclays lifted their target price on Elanco Animal Health from $18.00 to $19.00 and gave the company an "overweight" rating in a research report on Tuesday, February 27th. TheStreet upgraded Elanco Animal Health from a "d+" rating to a "c-" rating in a research report on Friday, February 23rd. The Goldman Sachs Group lifted their target price on Elanco Animal Health from $12.50 to $14.00 and gave the company a "sell" rating in a research report on Tuesday, February 27th. Morgan Stanley boosted their price objective on Elanco Animal Health from $16.00 to $17.00 and gave the company an "overweight" rating in a report on Tuesday, February 27th. Finally, Stifel Nicolaus upgraded Elanco Animal Health from a "hold" rating to a "buy" rating and boosted their price objective for the company from $13.00 to $20.00 in a report on Friday, January 5th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $16.71.

Elanco Animal Health Stock Down 2.0 %

ELAN traded down $0.27 on Thursday, hitting $13.04. 3,722,995 shares of the company were exchanged, compared to its average volume of 4,401,166. Elanco Animal Health Incorporated has a twelve month low of $7.88 and a twelve month high of $16.88. The company has a market cap of $6.44 billion, a price-to-earnings ratio of -5.22, a price-to-earnings-growth ratio of 1.41 and a beta of 1.29. The company has a current ratio of 2.75, a quick ratio of 1.35 and a debt-to-equity ratio of 0.92. The firm has a 50-day moving average price of $15.49 and a two-hundred day moving average price of $13.75.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its quarterly earnings data on Monday, February 26th. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.02). The business had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1 billion. Elanco Animal Health had a positive return on equity of 6.44% and a negative net margin of 27.87%. The company's revenue was up 5.1% compared to the same quarter last year. During the same period in the prior year, the company posted $0.19 earnings per share. On average, equities analysts predict that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Insider Transactions at Elanco Animal Health

In other Elanco Animal Health news, Director R David Hoover acquired 20,000 shares of the stock in a transaction dated Wednesday, March 6th. The stock was acquired at an average cost of $16.14 per share, with a total value of $322,800.00. Following the transaction, the director now owns 185,000 shares in the company, valued at approximately $2,985,900. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 6.40% of the company's stock.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.